Compare REKR & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | REKR | RFL |
|---|---|---|
| Founded | 2017 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Real Estate |
| Sector | Telecommunications | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.7M | 92.6M |
| IPO Year | 2017 | 2017 |
| Metric | REKR | RFL |
|---|---|---|
| Price | $0.69 | $2.23 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.2M | 364.7K |
| Earning Date | 05-13-2026 | 06-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 4.35 | ★ 28.28 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,234,000.00 | $917,000.00 |
| Revenue This Year | $12.51 | N/A |
| Revenue Next Year | $23.49 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 43.96 |
| 52 Week Low | $0.60 | $1.12 |
| 52 Week High | $3.42 | $3.96 |
| Indicator | REKR | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 48.57 | 46.75 |
| Support Level | $0.60 | $1.21 |
| Resistance Level | $0.74 | $3.96 |
| Average True Range (ATR) | 0.04 | 0.38 |
| MACD | 0.01 | -0.13 |
| Stochastic Oscillator | 67.41 | 4.42 |
Rekor Systems Inc is a roadway intelligence company focused on modernizing public safety, urban mobility, and transportation management through solutions. The company delivers services and solutions that collect, connect, and organize mobility data, providing real-time insights to support decision making, enhance situational awareness, enable rapid response, and support predictive analytics. The Company derives its revenues mainly from the licensing and sale of its roadway data and traffic management product and service offerings. These offerings include a mixture of data collection, implementation, engineering, customer support, and maintenance services, as well as software and hardware. The company operates in the United States and other regions.
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.